In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Kenneth Johnson
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Kenneth Johnson

First Name:Kenneth
Last Name:Johnson
Advanced Degrees:Ph.D.
Affiliation:Univ Texas Medical Branch
Street Address 1:301 University Blvd
Zip/Postal Code:77555-1031
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 21 February 2006]
View all comments by Kenneth Johnson
Clinical Interests:
Drug abuse, Schizophrenia
Research Focus:
Pharamacology, Animal models, Neurotransmission, Signal transduction, Neurodevelopment, Pharmacology, Glutamatergic transmission
Work Sector(s):
Web Sites:
Top Papers
1: Wang CZ, Johnson KM.
Differential effects of acute and subchronic administration on
phencyclidine-induced neurodegeneration in the perinatal rat.
J Neurosci Res. 2005 Jul 15;81(2):284-92.
PMID: 15948153 [PubMed - in process]

2: Wang C, Fridley J, Johnson KM.
The role of NMDA receptor upregulation in phencyclidine-induced cortical apoptosis in organotypic culture.
Biochem Pharmacol. 2005 May 1;69(9):1373-83.
PMID: 15826608 [PubMed - indexed for MEDLINE]

3: Wiley JL, Buhler KG, Lavecchia KL, Johnson KM.
Pharmacological challenge reveals long-term effects of perinatal phencyclidine on delayed spatial alternation in rats.
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):867-73.
PMID: 12921921 [PubMed - indexed for MEDLINE]

4: Wang C, McInnis J, West JB, Bao J, Anastasio N, Guidry JA, Ye Y, SalveminiD, Johnson KM.
Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic.
J Pharmacol Exp Ther. 2003 Jan;304(1):266-71.
PMID: 12490600 [PubMed - indexed for MEDLINE]

5: Yu B, Wang C, Liu J, Johnson KM, Gallagher JP.
Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors.
Neuroscience. 2002;113(1):1-10.
PMID: 12123679 [PubMed - indexed for MEDLINE]

6: Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia.
Neuroscience. 2001;107(4):535-50.
PMID: 11720778 [PubMed - indexed for MEDLINE]

7: Phillips M, Wang C, Johnson KM. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther. 2001 Mar;296(3):905-13.
PMID: 11181923 [PubMed - indexed for MEDLINE]

8: Wang C, Showalter VM, Hillman GR, Johnson KM.
Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat
forebrain. J Neurosci Res. 1999 Mar 15;55(6):762-9.
PMID: 10220116 [PubMed - indexed for MEDLINE]

9: Johnson KM, Phillips M, Wang C, Kevetter GA.
Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex.
J Neurosci Res. 1998 Jun 15;52(6):709-22.
PMID: 9669320 [PubMed - indexed for MEDLINE]

10: Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists.Trends Pharmacol Sci. 1990 Feb;11(2):81-6. Review.
PMID: 2156365 [PubMed - indexed for MEDLINE]
What is your leading hypothesis?
Genetic/environmental insults during development cause an overall loss in glutamatergic transmission, resulting in many maladaptive neuronal alterations. These changes can be modeled in rats to some extent by perinatal subchronic administration of NMDA antagonists like phencyclidine (PCP) on PN7, 9 and 11 which cause long-term cellular/molecular changes (e.g. NR1/2A upregulation, cortical apoptosis) and behavioral deficits (e.g. diminished PPI). These effects can be blocked by olanzapine. This model is distinct from that caused by acute acute administration on PN7 in that the toxicity and NMDAR upregulation are not susceptible to olanzapine or other antipsychotics. We propose that nderstanding the mechanisms underlying cell death and behavioral changes following PCP may lead to new therapeutic directions.

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright